Rare Disease Trial, Recruiting NCT03305835 Sponsor: Mayo Clinic Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT03305835
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children under 18 years old who have had kidney stones and/or calcium deposits in the kidneys (nephrocalcinosis)
  • Adults over 18 who have had kidney stones and/or calcium deposits in the kidneys, AND at least one of the following: a family history of kidney stones, calcium deposits, or unexplained kidney failure; slow or stunted growth; bone disease related to metabolism; unusual types of kidney stones or crystals in the urine; protein in the urine; reduced kidney function; abnormal levels of magnesium, phosphate, or calcium in the blood; high levels of oxalate; or cysts on the kidneys
  • People where a doctor strongly suspects they may have a genetic (inherited) kidney stone disease or a condition affecting how the body processes calcium
  • People who were previously enrolled in a related study called "Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria" (Rare Kidney Stone Consortium protocol 6406) and already gave consent for their samples to be used in genetic research
  • People who were previously enrolled in a related study called "Screening for Dent Disease Mutations in Patients with Proteinuria or Hypercalciuria and Calcium Urolithiasis" (Rare Kidney Stone Consortium protocol 6403) and already gave consent for their samples to be used in genetic research
  • A family member of anyone who meets any of the criteria listed above

Who may not be able to join:

  • People who have had kidney stones but do not meet the specific criteria that suggest a genetic cause for their condition
  • Anyone who is unwilling or unable to give their consent (or assent, for younger participants) to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David Sas, DO, Mayo Clinic

Phone: 800-270-4637

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
11 September 2017
Est. completion
1 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

symptomatic onset of monogenic stone disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov